Targets › MYL2
3 programs from 3 companies in 6 trials: 3 Phase 3, 2 Phase 4, 1 Phase 2; Cardiovascular; next expected readout Jun 2027.
Contractile protein that plays a role in heart development and function. Following phosphorylation, plays a role in cross-bridge cycling kinetics and cardiac muscle contraction by increasing myosin lever arm stiffness and promoting myosin head diffusion; as a consequence of the increase in maximum contraction force and calcium sensitivity of contraction force. (UniProt, P10916)
Open in Phaseline: the race on MYL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Mavacamten (BMS-986427) Cardiac myosin inhibitor | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 4 | Cardiomyopathy, Hypertrophic; Symptomatic Obstructive Hypertrophic Cardiomyopathy | Jun 2027 |
| Cytokinetics | Omecamtiv Mecarbil Cardiac myosin activator | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 3 | Heart Failure | Sep 2027 |
| Kardigan | danicamtiv Cardiac myosin activator | MYH7, MYH6, MYH7B, MYL3, MYL2 | Phase 3 | Symptomatic Genetic Dilated Cardiomyopathy (DCM); Symptomatic Genetic Dilated Cardiomyopathy | Sep 2027 |
Cardiomyopathy, Hypertrophic (2) Symptomatic Obstructive Hypertrophic Cardiomyopathy (1) Symptomatic Genetic Dilated Cardiomyopathy (DCM) (1) Symptomatic Genetic Dilated Cardiomyopathy (1) Heart Failure (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.